Bill Choy, Ph.D. MBA, ZC2 Consulting/pharmaceutical director. Bill got his BS in chemistry at UC-Berkeley, PhD in synthetic organic chemistry at UC-Santa Cruz, was a post-doc at MIT's chemistry department and got his MBA from Santa Clara University's executive MBA program. His industrial career (medicinal chemist and pre-clinical project manager) started in 1990 at Genelabs Technologies (now part of Glaxo Smith Kline since '09). He's a co-inventor of 5 US patents for drug discovery and process development and co-authored 15 publications in peer reviewed journals. His current consulting career started in '00 as a retained consultant for Genovate Biotech (Taiwan's 1st biotech company) and focusses on selecting in-vitro/in-vivo protocols, designing clinical protocols and strategic marketing research. Among his recent clients are entrepreneurs starting-up drug discovery companies in China.'

Kenneth Fong, Ph.D., is the Chairman of Kenson Ventures, LLC. Kenson specializes in venture financing and strategic consulting to biotech companies. As of January 2003, Kenson has 18 investments that mostly fall into 3 major categories: a) Innovative Research Tools, b) Platform Technologies, and c) Drug Development. Prior to founding Kenson, Dr. Fong was the founder and CEO of CLONTECH Laboratories that was acquired by Becton Dickinson (BD) in late 1999. CLONTECH was the leader in the Molecular/Cell Biology market and in the last 4 years before its acquisition, the company had experienced an average growth rate of 36% a year. The company also had 48 consecutive quarters of double-digit growth and profits. In 1994, 1995, 1998, and 1999, CLONTECH was selected as one of the fastest-growing companies in the San Francisco Bay Area. Dr. Fong's past experience is best suited to young companies and to those that desire to grow more rapidly. He is also adept at crafting development strategy and realistic implementation plans to promote the long-term growth of a company. Under Dr. Fong's leadership, companies that either were acquired or went public between 2007 and 2010 are: SA Biosciences (to Qiagen); DHI (to Quidel); Fermentas (to ThermoFisher); Panomics (to Affymetrix); Bioform (IPO); and Optimer (IPO). Dr. Fong obtained his Ph.D. from Indiana University.

Jian Gao, Ph.D. is an engineering development manager at Accuray, Inc., a medical device company specialized in high-precision radiation oncology systems. He has been involved in the R&D of CyberKnife® product, which is certified to treat tumors anywhere in the body with sub-millimeter precision. Prior to 2009, Dr. Gao was an engineering manager at GE for a number of years working on development of computed tomography systems. He has a Ph.D. biomedical engineering from the joint program between University of Memphis and University of Tennessee, and has a B.S. in Biomedical Engineering from Zhejiang University.

Ying Gong, Ph.D., received her PhD in Biochemistry and Molecular Biophysics from Caltech, studying the molecular mechanisms of vertebrate morphogenesis using zebrafish as a model. Upon graduation, she joined the management consulting firm Bain & Company, where she worked on a broad range of business strategy and operations projects in different industries. Dr. Gong joined Genentech in late 2007, where she has been responsible for commercial strategies of R&D programs in a number of therapeutic areas. Recently, she moved to a new position within Genentech and is responsible for developing reimbursement strategies.

Tao Huang, Ph.D., J.D., Legal and IP Counsel, Cenova Ventures. Dr. Tao Huang has over 20 years of combined experience in biomedical research, legal, and business in academia and the life sciences industry. At Cenova, Dr. Huang oversees IP strategy for portfolio companies. Prior to Cenova, Dr. Huang was an attorney at several prestigious law firms in the US, including Wilson Sonsini Goodrich & Rosati and Morgan Lewis & Bockius. Dr. Huang has been advising companies and investors in the biotechnology and pharmaceutical industries on a broad range of business and legal issues, including patent counseling, licensing, litigation, VC financing, M&A, and IPO. Dr. Huang has provided legal representation to several notable business transactions, including Takeda's licensing and collaboration deal with Alnylam relating to RNAi therapeutics (valued at $1 billion, with $100 million up-front fee), Ion Torrent's acquisition by Life Technologies ($375 million), and QuantaLife's acquisition by Bio-Rad Laboratories ($162million). Dr. Huang has also advised clients on high-stake litigation cases, including Brigham Young University v. Pfizer, Inc. (related to Celebrex, Pfizer paid $450 million to settle), and Life Technologies Corp. vs. Biosearch Technologies, Inc. (related to real-time PCR, settled). Dr. Huang received a B.S in Biophysics from Nankai University, a Ph.D. in Biochemistry from Peking Union Medical College/Chinese Academy of Medical Sciences, a J.D. from the University of Michigan Law School and his post-doctoral training in molecular biology and biochemistry from Princeton University. Dr. Huang is a registered United States Patent and Trademark Office attorney in the state of California.

Darren Ji, **Ph.D MBA**, Global Head, Roche Pharma Partnering - Asia and Emerging Markets, Genentech/Roche

Ruhong Jiang, Ph.D., is cofounder and CEO of Applied StemCell, Inc. located in San Francisco Bay area, chairman and CEO of Stanford Biotech, Inc. at China Medical City, Taizhou, Jiangsu Province in China. He has held a variety of technical and managerial roles with increasing responsibilities in several biotechnology/biopharmaceutical companies. Before starting Applied StemCell, Ruhong was general manager of MicuRx (Shanghai) Pharmaceutical, Inc. a California-based biopharmaceutical company where he set up its entire China operation. From 2005-2007, Dr. Jiang was head of the Pharmacogenetics Program at Stanford Research Institute International (SRI) where he managed multiple pharmacogenetic and molecular genetics projects with multi-millions of annual budget. Prior to relocating to California, Dr. Jiang was pharmacogenomics consultant at Boehringer Ingelheim Pharmaceuticals and served as senior scientist, then project manager at Genaissance Pharmaceuticals from 2000-2004 where he played an important role in biomarker discovery, pharmacogenetics and clinical bioinformatics, diagnostic product development, alliance management and business development. Dr. Jiang graduated from Fudan University with a B.S. degree in biology, and received M.S. degree in reproductive biology from China Agricultural University and a Ph.D. degree in Genetics from Oklahoma State University in 1997. From there Ruhong went to Baylor College of Medicine where he furthered his education as a postdoctoral fellow in Dr. Douglas Burrin's lab. Dr. Jiang has authored and co-authored more than 40 publications in the fields of human genetics, pharmacogenetics and disease animal models. Ruhong has a deep interest in the science, ethics and societal issues of personalized medicine, regenerative medicine and global health. His demonstrated leadership has led to an established track record of success; especially in the areas of biomarker-based molecular assays or diagnosis, CRO service, and drug research and development.

Cheni Kwok, Ph.D. CLP, Managing Partner & Founder, Linear Dreams LLC. Dr. Kwok is a Managing Partner of Linear Dreams LLC, a management consultancy and valuation software firm specialized in corporate strategy, business/corporate development, portfolio analysis, and valuation services for the life science industry. Prior to founding Linear Dreams LLC, Dr. Kwok served as Senior Vice President, Corporate Development at Poniard Pharmaceuticals Inc., where she established corporate and business development, strategic and commercial planning, new product planning, competitive intelligence and forecasting functions. Previously, Dr. Kwok was Director of Business Development at Celera Genomics Inc., where she led the business development efforts for Celera's small molecule therapeutics. Dr. Kwok held business development positions of increasing responsibility for Exelixis Inc., where she initiated multiple partnerships and served as the alliance manager for the GlaxoSmithKline PLC (GSK) collaboration. Prior to joining Exelixis Inc., Dr. Kwok held various research management, technology assessment and alliance management roles at SmithKline Beecham PLC (now GSK). Dr. Kwok received a bachelor's degree in biotechnology from the Imperial College of Science, Technology and Medicine, University of London, UK, and a Ph.D. in human molecular genetics from the University of Cambridge, UK. Dr. Kwok has earned the Certified Licensing Professional (CLP) credential awarded by the Licensing Executives Society.

Jia Li, Ph.D., is currently Executive Director of Business Development and Head of Client Service Division at Crown Bioscience. She is also an Investment Advisor Representative of Transamerica Financial Group. Prior to transitioning into business world, she was a structural biologist at Exelixis and Zyomyx. She obtained her Ph.D. in Molecular Physiology and Biological Physics from University of Virginia and her B.Sc in Chemistry from Nanjing University.

Leping Li, Ph.D., serves as the Vice President of Chemistry at Presidio Pharmaceuticals, Inc. a San Francisco-based biopharmaceutical company. Prior to joining Presidio in 2007, Dr. Li held various scientific management positions at Amgen (and formerly Tularik), most recently as a Scientific Director in medicinal chemistry. Dr. Li's professional career also includes a 7-year stay at Abbott Laboratories during the late 1990s. Dr Li was trained as an organic chemist with a Ph.D. degree from Rice University and a postdoctoral fellowship at Stanford University. He graduated from Shandong University in 1983; the following year he came to the USA on an exchange fellowship

(CGP). In his nearly 20 years' professional career both with large and small companies, he has been involved in drug discovery programs from early lead identification to advanced clinical development stages across several therapeutic areas, including infectious diseases, cancers and metabolic disorders.

Charlene Liao, Ph.D., holds Ph.D. in Biology from Brandeis University and a B.S. in Biochemistry from Peking University. She conducted postdoctoral research in immunology and signal transduction at UCSF where she was a Fellow of the Damon Runyon Cancer Research Fund and a Special Fellow of the Leukemia and Lymphoma Society of America. Dr. Liao began her bio-pharmaceutical industry career at Tularik Inc. (now Amgen) as a Scientist. Prior to joining Genentech Dr. Liao held various leadership positions at Rigel Inc., including Project Leader, Associate Director, and Director of Business Development. Dr. Liao joined Genentech in 2002 and has been a Project Team Leader since 2007. She has contributed to IND filing for 8 NMEs including large and small molecule drugs and across the therapeutic areas of oncology, immunology and infectious diseases. Dr. Liao is one of the founding members and Board of Directors of the Ray Wu Memorial Fund, and a part of the "Executive Program for Women Leaders" at Stanford Graduate School of Business last year.

Harry Liu, MPH. MBA, has been working in the area of Drug Safety and Pharmacovigilance for the past 10 years. Most recently, he is Sr. Safety Scientist in Roche/Genentech responsible for an oncology molecule in late stage development. Previously, he worked in Amgen in the area of drug safety, pharmacovigilance, and pharmacoepidemiology. He also worked in Johnson & Johnson, and conducted medical research in UCSF. He has a medical degree from Jilin University, a MPH from UC Berkeley, and a MBA from UCLA.

Zheng (Jen) Liu, J.D, Zheng (Jen)'s practice focuses on patent, trade secrets, and unfair competition litigation, intellectual property counseling, due diligence and technology transactions across a broad range of industries, including biotechnology, pharmaceutical, medical devices, Internet and telecommunications. She advises Chinese companies on a wide range of legal issues specific to Chinese companies doing business in the United States, particularly in intellectual property, technology law, and commercial disputes. Some of the Chinese companies she has advised are Tencent, Foxit, UCWeb etc. She has also been the lead member for many patent infringement and commercial litigation cases and has argued important issues such as claim construction and examined witnesses in federal courts. Before joining Orrick, Ms. Liu was an associate at a prominent IP litigation boutique firm, where she was involved in matters for Amgen Inc., Angiotech Pharmaceuticals Inc., Isis Pharmaceutical Inc., Napo Pharmaceuticals, Inc., and Lily ICOS LLC. Ms. Liu worked in anti-viral drug development at Johnson & Johnson between graduate school and law school, therefore understands the science and process of drug development as well as the business objectives of corporations. Ms. Liu was born and raised in China. She has served on the Executive Committee of the Berkeley Chinese Alumni International Association and on the board of the University of Science & Technology (USTC) Alumni Association. She is also the current President of Chinese Lawyers' Association in the Bay Area (CALOBA). She has been active in promoting mutually beneficial legal and business relationships between the United States and China, helping Chinese law students and junior lawyers succeed in the United States, and lecturing Chinese companies and technology associations on legal issues faced by Chinese companies or professionals. She also writes articles for Chinese language publications, such as the prestigious Caijing magazine, on issues of U.S. law. She also provides pro bono legal services for victims of domestic violence.

Cheng Liu, Ph.D., is the founder and CEO of Eureka Therapeutics, a California Biotech Company dedicated to antibody research and discovery for next-generation cancer therapeutics. Prior to founding Eureka, Dr. Liu was a Principal Scientist in Antibody Drug Discovery at Chiron Corporation (now part of Novartis), where he championed the anti-CSF1 antibody program for treatment of bone metastasis. The program is currently in human clinical trials. Dr. Liu is the lead inventor of more than ten drug discovery patents filed in the US and Europe. In 2007, he was awarded Special Congressional Recognition for his contributions to improving human health. Dr. Liu received his B.S. in Cell Biology and Genetics from Beijing University and a Ph.D. in Molecular Cell Biology from the University of California, Berkeley.

Ruben Luo, Ph.D., is a product manager at Bio-Rad Laboratories, one of the largest biotechnology equipment suppliers. He is responsible for the R&D, global marketing, and manufacturing of a capital instrument product line with over $10 million annual revenue. Before joining Bio-Rad Laboratories, he was a graduate student in the

Department of Chemistry in Stanford University, and obtained his PhD degree in the summer of 2008. He received his BS degree in 2003 in the Department of Chemistry in Peking University, where he was awarded three times the first-class and once the second-class yearly scholarships.

Jiangwen Majeti, Ph.D. MBA is currently the Director of Business Development, BioDuro, a PPD company. She transitioned from a senior research scientist position at Amgen to the business development role at BioDuro after the completion of her MBA in 2011. She brings over 10 years drug discovery experience in the biopharmaceuticals industry to her current post. While at Amgen, Dr. Majeti led research efforts in both small molecule and biologics drug discovery programs. Prior to joining Amgen, she was a scientist in the Discovery Biology Group at GPC Biotech, Waltham, MA. Dr. Majeti graduated from Fudan University, China with a B.S. in Biochemistry and holds a Ph.D. in Molecular Genetics from the University of Wisconsin at Madison followed by postdoctoral training at the Howard Hughes Medical Institute at the University of California, San Francisco. She also holds a MBA degree from Leavey School of Business at Santa Clara University.

Shichang Miao, Ph.D., is a past president of CABS (2009-2010). He is employed as Senior Director, Discovery & Clinical Drug Metabolism / Pharmacokinetics at ChemoCentryx Inc., a public biotech company focusing on the drug discovery and development through regulation of chemokine receptors. Previously, he was a director in the pharmacokinetics and drug metabolism department at Amgen South San Francisco. He worked at Tularik Inc. from 1994 through 2004 (most recently as Associate Director, Analytical Chemistry and Drug Metabolism) until Tularik's acquisition by Amgen. He holds a Ph.D. in organic chemistry / natural products chemistry from the University of British Columbia (Vancouver) and carried out postdoctoral research in organic chemistry and biochemistry. In addition to his CABS leadership activities, he is also the founder and president of CACO Pharmaceutical & BioScience Society (CACO-PBS), a professional organization of 3000+ members with chapters in the San Francisco Bay Area and San Diego.

Hing Sham, Ph.D., has 30 years of drug discovery experience in five therapeutic areas including neuroscience, oncology, infectious diseases, metabolic diseases and cardiovascular diseases, delivering multiple clinical candidates for clinical development; inventor of two HIV drugs (Norvir and Kaletra, both HIV Protease inhibitors) that were approved by the FDA and EMEA, with one of them (Kaletra) having blockbuster sales (over a billion dollars per year) every year since 2005. Named National Inventor of the Year in 1997 by Intellectual Property Owners-Washington DC; named Inventor of the year two times by the Intellectual Property Law Association of Chicago (1997 & 2004); named Hero of Chemistry by the American Chemical Society in 2003 for the invention of Kaletra; named the 2011 Distinguished Alumni by the University of Hawaii Alumni Association. From 2006 to 2012, Dr. Sham led the drug discovery effort at Elan in the area of Parkinson's and Alzheimer's diseases as the Head of the Chemical Sciences department until November 2012. Currently Dr. Sham is the Head of Research and preclinical development at PATH-a non-profit organization, responsible for finding novel therapeutics for diseases that are of particular high burden in developing countries e.g. diarrheal diseases. His specialties include medicinal chemistry; drug discovery; structure based drug design; project management.

Zhenhai Shen, Ph.D., MBA, is current Head for Research Services Procurement at Genentech/Roche responsible for research outsourcing activities for both Genentech and Roche. He received his Ph.D. Degree from The Mount Sinai School of Medicine and completed his postdoctoral training at Dana-Farber Cancer Institute. Zhenhai also holds a MBA degree from Ross School of Business of University of Michigan. Prior to Genentech, Zhenhai worked in Eli Lilly's International Finance group.

Hong Tan, Ph.D., the CEO of ET Healthcare that develops, manufactures and markets innovative diagnostic instruments and reagents. In early 2000, Hong founded Wave Crossing Corporation, and served as CEO and President. He established its wholly owned Chinese subsidiary where a novel GRIN lens (a key fiber optic component) was developed and commercialized. In late 2001, Hong founded ForteBio, Inc. where he created Octet for label-free analysis of molecular interactions. ForteBio was later acquired by Pall, Inc in December 2011. Prior to his entrepreneurial career, Hong designed data storage devices at Iomega, Maxtor, Seagate, Conner Tech, and Caleb Tech. His experience also includes developing control systems for NASA space telescopes. He holds PhD and

MSEE from Auburn University, BSEE from Xi'an Jiao Tong University, and EMBA degree from Cheung Kong Graduate School of Business in Beijing.

Jay Tong, **Ph.D,** CEO and founder of AllCells, LLC. AllCells is located in the San Francisco Bay Area in Alameda, CA as well as in Shanghai. Today, AllCells is a world leading provider of human primary cells and services to the research community. Dr. Tong earned his M.D. from Suzhou Medical College in China 1984. He then took his graduate studies from Henan Medical University at Zheng Zhou of China in Hematology from 1984-1987. He later completed his Hematology Fellowship at the prestigious Genoa Medical School in Italy, a world leader in bon e marrow transplantation in 1991. Additional Post-Doctoral training took him to the well known Dr. Ronald Hoffman's Lab at Indiana University Medical School at Indianapolis from 1991-1993. His first job as a research scientist was at Novartis-Systemix in Palo Alto, Ca from 1993-1998. Dr Tong has published over thirty (30) peer-reviewed papers relating to stem cell purification, ex vivo expansion, gene transduction and transplantation of hematopoietic stem cells. The Birth Of A Business Idea - While working at Novartis-Systemix, Dr Tong grew increasingly frustrated by the lack of human primary hematopoietic & immunological cell sources to complete his research projects. There was either an unreliable or non exist source of these essential elements available, so he set out to provide this missing link, which today is the major focus of the company's business plan. Since this was a ground breaking and novel idea, he was not able to secure financing to pursue his dream. Dr Tong started his business with his last $20,000 of personal savings. The business started in a small corner of a lab in Berkeley. After a couple of years as a one man shop, long days and weekends, the company with modest beginnings has now grown to occupy about 30,000 square feet in Alameda, Ca with >50 employees handling its business development, R&D, sales, clinical operations and daily operations for this rapidly growing company. In 2012, AllCells was ranked 2,420 on the prestigious Inc. 500/5000 list of fastest growing companies. AllCells ranked 194 within the Health industry segment. In 2010 and 2011, AllCells was ranked for two consecutive years among Fast 50 Asian American Businesses by the Washington DC-based US Pan Asian American Chamber of Commerce Education Foundation (USPAACC). AllCells-Shanghai was also established in XuHui District in 2003 and serving Chinese research community for its animal primary cell needs. AllCells-Shanghai has about 20 employees with about 10,000 square feet facilities.

DQ Wang, Ph.D. is currently located in Beijing and responsible for Bayer's potential investment projects in China. DQ had his BS degree in Engineering in China, and MS and Ph.D degree also in Engineering in the U.S. He started his career with 5 years of process development experience in a start-up biotech company in the US. Then he has spent the last 19 years at Bayer Biotech in the US, from a Production Engineer to a Dept. Head. He has been a leading scientist and technical manager in development, scale-up, process transfer and production of many biotech products at Bayer Biotech including the Bayer's blockbuster drug KogenateTM. In the past, D.Q. served as the Chairman of Industrial Advisory Board for the U.S. National Science Foundation Research Center for Pharmaceutical Processing, an adjunct professor in Industrial Pharmaceutics at Purdue University; and an adjunct professor of Peking University, He was also the President of CABS (Chinese American BioPharmaceutical Society) 2003-2004 in the US.

Yingfei Wei, Ph.D., joined 3SBio in August 2006. She has over fifteen years of research and development experience in the biotechnology and pharmaceutical sectors. Before joining 3SBio, Dr. Wei was the Co-founder, President and Chief Executive Officer of Elixirin Corporation from 2004 to 2005, responsible for overseeing contract research, manufacturing, regulatory approvals and marketing of anti-aging products in the U.S. and China. Prior to that, she was Director of Biotechnology Research at Bayer HealthCare Global from 1998 to 2004 and group leader at the discovery research department of Human Genome Sciences Inc. from 1993 to 1998. Dr. Wei is the inventor of 37 patents and has authored several publications, primarily in the areas of protein and antibody drug discovery and genomics. Dr. Wei was a postdoctoral fellow at Harvard University's School of Public Health in 1993.

She received her Ph.D. in biochemistry from the University of California in 1990 and a bachelor's degree in biochemistry from Beijing University in 1983.

Alex Wu, Ph.D. MBA, is co-founder & CEO of Crown Bioscience, a premier drug discovery company providing cutting-edge translational platforms and world class drug discovery solutions for its biotech and pharmaceutical partners in dedicated therapeutic areas of oncology and metabolic diseases. The company is headquartered in California with research facilities in China, North Carolina and UK. It counts 18 of the top 20 global pharmaceutical companies and many biotech companies as its partners. Before joining Crown, he was CBO of Starvax International, a development stage biotech company specialized in oncology and infectious diseases. Prior to Starvax, Alex was with Burrill & Company, a world leading life sciences merchant bank and venture capital firm. Before joining the venture capital industry, Alex was involved in several start-ups, one of which was Unimicro Technologies, Inc. He also worked for Hoffmannn-La Roche as Manager of Business Development and Strategic Planning. Dr. Wu received B.S. from Fudan University in Shanghai, China and Ph.D. in Molecular and Cell Biology and MBA from the University of California, Berkeley. He conducted post-doctoral research at Stanford University.

Vincent Xiang, Ph.D MBA, Managing Director of International Investments and Business Development of Humanwell Healthcare Group. Dr. Xiang obtained his Ph. D degree in molecular biology from SBU and later MBA degree from Wharton. In 2013, Dr. Xiang's research CPR15-mediated homing control immune homeostasis in the large intestine mucosa was published on Science. Dr. Xiang has over 20 years of experience in biopharma industry and has invested global life science firms at all stages. He had served as managing director of Burrill & Company and later as vice president in Franklin Templeton Inv, co-managing the Franklin Biotech Discovery Fund. Dr. Xiang is also an active participant in promoting industry communications between China and US, being the founding member of BayHelix Group and member of CABS and SAPA.

Janet (Jian) Xiao, Ph.D., J.D., is a partner in Morrison & Foerster's Life Science Group residing in the Palo Alto office. She primarily represents clients in the biotechnology and pharmaceutical industries in their world-wide patent procurement, patent portfolio management, and strategic planning. Dr. Xiao has significant experience in developing and strengthening her clients' complex patent portfolios to maximize their commercial value and success. She advises biopharmaceutical companies such as Celgene and Genentech and research institutions such as University of California on patent matters relating to various technologies including antibody therapeutics, personalized medicine, drug delivery systems, drug screening platforms, diagnostics, and nutraceuticals. She also represents many start-up biopharmaceutical companies to help them build a strong IP position from the inception. She also prepares legal opinions on patent validity and freedom to operate, conducts IP due diligence reviews for business transactions, and is among the very few IP attorneys who are both equipped with solid skills in global strategic IP management and knowledgeable about IP issue unique to China. She is frequently called upon to advise clients on IP issues relating to US/China cross-border transactions and operations in China, and is frequently invited to speak on IP issues both in the US and in China.

Shelly Xiong, Ph.D., RAC is currently a director of Regulatory Affairs at InterMune, Inc. She has 20 years of pharmaceutical industrial experiences across a broad spectrum of drug development processes. She has extensive experiences in drug discovery, clinical development, regulatory strategy, and commercial activities. Prior to InterMune, she held various leadership positions at Gilead Sciences (regulatory affairs; principal scientist in clinical virology) and Covance (Director of China Operations). She was also a co-founder and Chief scientific Officer of a China-based start-up company. She received her Ph.D. in Biochemistry from University of Wisconsin-Madison and B.S. in Chemistry from Beijing University.

Gary Yeung, **MBA**, Head of gRED project management, Genentech/Roche, is a Senior Director of Portfolio Management and Operations at Genentech. He has 15 years of biotech and health care consulting experience. In his current role, he oversees the project management of Genentech drug development portfolio. His other leadership roles at Genentech include Portfolio Planning, Finance and Commercial Operations. Before Genentech, Gary advised health care clients at McKinsey, implemented corporate strategies at GE and raised capital and closed multiple partnerships at Cerus. Gary received his BS in Chemical Engineering from UC Berkeley, holds an MBA from UCLA and is a Chartered Finance Analyst (CFA) and certified Project Management Professional (PMP).

Guo-Liang Yu, Ph.D., is executive Chairman, Crown Bioscience Inc., an emerging biotech company with 400 employees dedicated to the development of personalized cancer therapeutics. Guo-Liang cofounded Epitomics, a leading monoclonal antibody company. Guo-Liang was Senior Vice-President of Research and Development at Mendel Biotechnology Inc. where his team analyzed the function of a complete set of plant transcription factors by knock-out and over-expression in planta. Guo-Liang was a Senior Scientist at Human Genome Sciences Inc. where he discovered the target Blys for the lupus drug belimumab. Guo-Liang was trained at Harvard Medical School as a postdoctoral fellow and earned a Ph.D. degree with Nobel Laureate Dr. Elizabeth Blackburn in Molecular Biology from the University of California, Berkeley and B.S. degree in Biochemistry from Fudan University in Shanghai. Guo-Liang is a co-inventor of more than 200 patents and a co-author of 40 scientific articles. Guo-Liang is the founding president of Chinese Biopharmaceutical Association and service on several professional organizations in the US and China as a member of the board of directors or board of advisory.

Jack Zhai, Ph.D., also known by his Chinese name of Zhai Ye, was among the first 100 outstanding talents selected by the Chinese government in 1987 to qualify for fully financially-funded overseas graduate studies. Before pursuing his PhD in Cell and Molecular Biology at the University of Wisconsin-Madison in 1987, Jack received his MS degree in Biophysics at the Chinese Academy of Agriculture Sciences and also received comprehensive training in fine instrumentation at Qinhua University, one of the most prestigious Universities in the world. In 1993, Jack received his PhD at the University of Wisconsin-Madison and completed his Hooper Foundation Postdoctoral Fellowship at the University of California, San Francisco. He nearly completed (MBA) business training at the Haas School of Business, UC Berkeley. Jack has more than 20 years experience within the life sciences industry, having expertise in the areas of cell biology, cancer biology, and genomics. Jack has published a number of important research papers regarding cell division and mitosis in peer-reviewed journals such as "Journal of Cell Biology". His two important discovery publications about microtubule dynamics during mitosis have been incorporated into today's "Cell Biology" text book edited by Bruce Alberts, and Dr. Zhai has important technology patents with the University of California San Francisco. Jack Zhai also has 15 years of experience working for Fortune 500 companies including Applied Biosystems, Invitrogen, and Millipore including roles involving technology commercialization, product management, strategic marketing and sales, and technology licensing. Currently, Jack serves as the Vice President of Sales and Marketing at AllCells, LLC, a leading global provider of human primary cells and related services for the life science industry, based in the San Francisco Bay Area. Jack is recognized as a biotechnology authority in the Asia Pacific region and has been invited by the Chinese government and Hong Kong to give speeches on the state of the Chinese biotech business. Besides Jack's tenure in the life sciences industry, since 2000 he has served as a Biotech Business Consultant for the Chinese International Talent Development Center at the Foreign Liaison Department, an adjunct professor at Shanghai Institute of Microsystems, Chinese Academy of Sciences, and an adjunct professor at Business School of Northwest University at Xi'an.

Tony (Dongxiao) Zhang, Ph.D., is the co-founder, President and CEO of Formurex, Inc., a pharmaceutical CRO in Stockton, CA. He is also an adjunct professor in the Department of Pharmaceutics and Medicinal Chemistry at University of the Pacific in Stockton, California. Prior to co-founding Formurex, Dr. Zhang was the co-founder and vice president of Epitomics, Inc., a leading antibody company in Burlingame, California. At Epitomics, Dr. Zhang led the technology development and was awarded by the U.S. government with multiple SBIR grants (Phase I and II). Prior to his Epitomics venture, Dr. Zhang was a senior research scientist at Bayer Corporation. At Bayer, Dr. Zhang headed a high throughput screening (HTS) group to screen for novel drug leads and to discover antibody targets for cancer therapeutics. Dr. Zhang obtained his Ph.D. in Biochemistry at Case Western Reserve University and did his postdoctoral research at Genentech, where he developed genomic technologies and discovered novel drug

targets. He received his MBA degree from St. Mary's College in California. He is a member of several Chinese-American associations including BayHelix, CABS, and CBA.

Wentao Zhang, Ph.D., is Founder of Quintara Discovery, a biotech company focusing on drug discovery and development services that include in vitro ADME, bioanalysis and assay development in South San Francisco. Previously, Dr. Zhang was Senior Director of Lead Discovery at Exelixis from 2001 to 2012, managing key drug discovery platform and functions that include compound library management, assay development and high-throughput screen efforts, lead optimization, ADME operations and HERG safety pharmacology. Dr. Zhang has worked extensively in targeted drug discovery covering kinases, GPCR's and nuclear hormone receptors using a wide spectrum of enabling technologies. The drug discovery technology platform that Dr. Zhang helped to establish has generated and progressed over 20 compounds from discovery to clinical development, including candidates in phase 2 and 3 clinical trials, and Cometriq™, a novel kinase inhibitor approved for medullary thyroid cancer by the FDA in 2012. Before that, Dr. Zhang was a Staff Scientist at Genelabs Technologies from 1999 to 2001 responsible for biochemical and biophysical assays in the therapeutic areas of oncology and infectious diseases. In 1997-1999, Dr. Zhang was a postdoctoral fellow at University of California-Berkeley. He obtained his Ph.D. from University of Wisconsin-Madison, M.S. from Emory University and B.S. from Peking University. Dr. Zhang has published extensively in peer-reviewed scientific journals and holds multiple patents. He has been actively involved in various professional services and organizations, including serving on the NIH study section on assay development. Dr. Zhang has extensive management experience and has played key leadership roles in various biopharmaceutical companies. Dr. Zhang was President of the Chinese-American Biopharmaceutical Society (CABS) in 2012-13.